Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal
· seekingalpha.com
Arvinas, Pfizer & Rigel’s Veppanu licensing deal is now active after U.S. antitrust clearance—$70M upfront plus up to $320M milestones.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...